The intranasal vaccine iNCOVACC from Bharat Biotech International Limited (BBIL) is priced at Rs 800 for private markets and Rs 325 for government supplies, excluding GST. On the CoWIN site, the vaccine is available.
Bharat Biotech stated in a press release on Tuesday that the jab will be released in the fourth week of January 2023.
iNCOVACC is the first intranasal Covid vaccination approved for both the primary two-dose schedule and the heterologous booster dose. Earlier in December, the manufacturer of the vaccine obtained permission from the Central Drugs Standard Control Organisation (CDSO).
According to the press announcement, Phase-III trials of iNCOVACC (as a two-dose regimen) were undertaken for safety and immunogenicity on about 3,100 patients at 14 trial sites in India. In 875 patients, safety and immunogenicity investigations for the heterologous booster dose were done.
Krishna Ella, Executive Chairman of BBIL, stated, “We have developed Covaxin and iNCOVACC, two COVID vaccines based on two different platforms and with two distinct delivery systems. The vectored intranasal delivery platform enables rapid product development, scalability, and simple, painless immunisation during public health emergencies and pandemics.”
iNCOVACC was created in collaboration with Washington University in St. Louis, which designed and developed the recombinant adenoviral vectored construct and tested its efficacy in pre-clinical investigations.